Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.72bn
- Net income in CHF654.00m
- Incorporated2002
- Employees18.00k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
Mergers & acquisitions
Acquired company | LONN:SWX since announced | Transaction value |
---|---|---|
Genentech Inc-Biologics Manufacturing Facility,Vacaville,California | 6.43% | 1.20bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zealand Pharma A/S | 44.65m | -95.81m | 7.83bn | 270.00 | -- | 18.66 | -- | 175.31 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
Qiagen NV | 1.72bn | 299.66m | 8.24bn | 5.90k | 28.06 | 2.63 | 17.02 | 4.78 | 1.38 | 1.38 | 7.97 | 14.78 | 0.3209 | 1.84 | 5.64 | 298,708.00 | 5.58 | 5.41 | 6.63 | 6.53 | 62.78 | 64.65 | 17.38 | 16.35 | 1.45 | -- | 0.2946 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Genmab A/S | 2.30bn | 706.94m | 15.88bn | 2.29k | 22.36 | 3.71 | -- | 6.89 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
argenx SE | 1.25bn | -291.52m | 24.76bn | 1.15k | -- | -- | -- | 19.77 | -5.20 | -5.20 | 22.34 | -- | -- | -- | -- | 1,127,731.00 | -- | -17.65 | -- | -19.79 | 89.87 | -- | -23.28 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
Lonza Group AG | 6.72bn | 654.00m | 37.38bn | 18.00k | 58.38 | 3.95 | 30.42 | 5.57 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 04 Jul 2024 | 2.53m | 3.50% |
Norges Bank Investment Managementas of 17 Jul 2024 | 2.17m | 3.01% |
UBS Asset Management Switzerland AGas of 02 Jul 2024 | 1.78m | 2.47% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 1.29m | 1.79% |
Z�rcher Kantonalbank (Investment Management)as of 31 May 2024 | 1.17m | 1.62% |
Credit Suisse Asset Management (Schweiz) AGas of 28 Jun 2024 | 1.04m | 1.45% |
BlackRock Investment Management (UK) Ltd.as of 18 Jul 2024 | 1.02m | 1.41% |
Invesco Advisers, Inc.as of 30 Jun 2024 | 892.88k | 1.24% |
BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 877.29k | 1.22% |
Schroder Investment Management Ltd.as of 31 May 2024 | 855.00k | 1.18% |